{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:08:48Z","timestamp":1790701728326,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01602-y","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:52:27Z","timestamp":1790700747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Chemoimmunotherapy for Resectable Gastric and Gastroesophageal Junction Cancer: A Conceptual, Biomarker-Informed, and Regionally Adapted Framework"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"1602_CR1","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Stomach Cancer."},{"key":"1602_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1602_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"1602_CR4","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"1602_CR5","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Homann N, Pauligk C, FLOT4-AIO Investigators, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"1602_CR6","doi-asserted-by":"crossref","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, ACTS-GC Group, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","DOI":"10.1056\/NEJMoa072252"},{"key":"1602_CR7","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387\u201393.","journal-title":"J Clin Oncol"},{"key":"1602_CR8","doi-asserted-by":"crossref","unstructured":"Bang YJ, Kim YW, Yang HK, CLASSIC trial investigators, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315\u201321.","DOI":"10.1016\/S0140-6736(11)61873-4"},{"key":"1602_CR9","doi-asserted-by":"crossref","unstructured":"Noh SH, Park SR, Yang HK, CLASSIC trial investigators, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396.","DOI":"10.1016\/S1470-2045(14)70473-5"},{"key":"1602_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296\u2013304.","journal-title":"J Clin Oncol"},{"key":"1602_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10120-023-01419-9","volume":"26","author":"Y Kodera","year":"2023","unstructured":"Kodera Y, Yoshida K, Kochi M, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer. 2023;26:1063\u20138. https:\/\/doi.org\/10.1007\/s10120-023-01419-9.","journal-title":"Gastric Cancer"},{"key":"1602_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"1602_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10120-025-01698-4","volume":"29","author":"Japanese Gastric Cancer Association","year":"2026","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29:271\u201399. https:\/\/doi.org\/10.1007\/s10120-025-01698-4.","journal-title":"Gastric Cancer"},{"key":"1602_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"1602_CR15","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2026. https:\/\/www.nccn.org"},{"key":"1602_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393:217\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"1602_CR17","doi-asserted-by":"publisher","first-page":"S1738","DOI":"10.1016\/j.annonc.2025.09.096","volume":"36","author":"J Tabernero","year":"2025","unstructured":"Tabernero J, Al-Batran SE, Wainberg ZA, et al. Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: a randomised, phase III study of durvalumab plus FLOT in resectable gastric\/gastroesophageal junction adenocarcinoma. Ann Oncol. 2025;36(suppl 2):S1738-9. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.096.","journal-title":"Ann Oncol"},{"key":"1602_CR18","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, Rha SY, Wyrwicz L, et al. Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study. J Clin Oncol. 2025;43:3152\u20139. https:\/\/doi.org\/10.1200\/JCO-25-00486.","journal-title":"J Clin Oncol"},{"key":"1602_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz L, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of a multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25:212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"key":"1602_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus adjuvant chemotherapy after D2 or more extensive lymph-node dissection for stage III gastric or gastroesophageal junction cancer (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9:817\u201328.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1602_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","volume":"19","author":"A Cats","year":"2018","unstructured":"Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:616\u201328.","journal-title":"Lancet Oncol"},{"key":"1602_CR22","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","volume":"33","author":"SH Park","year":"2015","unstructured":"Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the ARTIST trial. J Clin Oncol. 2015;33:3130\u20136.","journal-title":"J Clin Oncol"},{"key":"1602_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","volume":"32","author":"SH Park","year":"2021","unstructured":"Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S-1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32:368\u201374.","journal-title":"Ann Oncol"},{"key":"1602_CR24","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903\u201313.","journal-title":"J Clin Oncol"},{"key":"1602_CR25","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Yook JH, Park YK, et al. Long-term outcomes of the PRODIGY trial of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for locally advanced gastric cancer. J Clin Oncol. 2024;42:2681\u201390.","journal-title":"J Clin Oncol"},{"key":"1602_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26:312\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(24)00676-4.","journal-title":"Lancet Oncol"},{"issue":"3suppl","key":"1602_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2024.42.3_suppl.247","volume":"42","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz L, et al. Pembrolizumab plus FLOT versus FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: interim analysis of the phase 3 KEYNOTE-585 FLOT cohort. J Clin Oncol. 2024;42(3suppl):247. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.247.","journal-title":"J Clin Oncol"},{"issue":"2suppl","key":"1602_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1200\/JCO.2026.44.2_suppl.353","volume":"44","author":"D Molena","year":"2026","unstructured":"Molena D, Hyung WJ, Wainberg ZA, et al. Surgical journey for participants in the MATTERHORN trial. J Clin Oncol. 2026;44(2suppl):353. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.353.","journal-title":"J Clin Oncol"},{"key":"1602_CR29","first-page":"1100315","volume":"13","author":"L Shen","year":"2023","unstructured":"Shen L, Kang YK, Chen Z, et al. Effect of nivolumab plus chemotherapy as neoadjuvant treatment for patients with resectable gastric and gastroesophageal junction cancer: an exploratory analysis of CheckMate 649. Front Oncol. 2023;13:1100315.","journal-title":"Front Oncol"},{"key":"1602_CR30","unstructured":"U.S. Food and Drug Administration. FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma. 2025."},{"key":"1602_CR31","unstructured":"European Medicines Agency. Imfinzi (durvalumab): European Public Assessment Report, gastric or gastro-oesophageal junction adenocarcinoma indication. Updated May 18, 2026. Accessed August 30. 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imfinzi"},{"key":"1602_CR32","unstructured":"Pharmaceuticals and Medical Devices Agency. Approval review information: Imfinzi intravenous infusion 120 mg and 500 mg (durvalumab), FY2026. Accessed August 30. 2026. https:\/\/www.pmda.go.jp\/drugs\/2026\/P20260721001\/navi.html"},{"key":"1602_CR33","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong T, Smithers BM, Michael M, et al. Preoperative chemoradiotherapy for resectable gastric cancer (TOPGEAR): a randomized phase III trial. N Engl J Med. 2024;391:1810\u201321.","journal-title":"N Engl J Med"},{"key":"1602_CR34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","volume":"49","author":"SE Al-Batran","year":"2013","unstructured":"Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: FLOT65+. Eur J Cancer. 2013;49:835\u201342.","journal-title":"Eur J Cancer"},{"key":"1602_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.07.004","author":"PA Ding","year":"2026","unstructured":"Ding PA, Yang S, Meng LJ, et al. A multimodal deep learning model for preoperative prediction of postoperative complications in gastric cancer. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.07.004.","journal-title":"Ann Oncol"},{"key":"1602_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the MAGIC trial. JAMA Oncol. 2017;3:1197\u2013203.","journal-title":"JAMA Oncol"},{"key":"1602_CR37","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392\u2013400.","journal-title":"J Clin Oncol"},{"key":"1602_CR38","first-page":"41","volume":"75","author":"GM Haag","year":"2019","unstructured":"Haag GM, Czink E, Ahadova A, et al. Prognostic significance of microsatellite instability in microsatellite-instable gastric and gastroesophageal junction cancer receiving neoadjuvant treatment. Cancer Treat Rev. 2019;75:41\u20138.","journal-title":"Cancer Treat Rev"},{"key":"1602_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andre","year":"2023","unstructured":"Andre T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized dMMR\/MSI-H gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41:255\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00686.","journal-title":"J Clin Oncol"},{"key":"1602_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2025","unstructured":"Raimondi A, Lonardi S, Murgioni S, et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann Oncol. 2025;36:285\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.016.","journal-title":"Ann Oncol"},{"key":"1602_CR41","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi M, Verschoor YL, Tan PB, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390:1949\u201358.","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"1602_CR42","first-page":"307","volume":"41","author":"J Chao","year":"2023","unstructured":"Chao J, Gao JJ, Hrynuk J, et al. Neoadjuvant immunotherapy for MSI-H resectable gastric\/gastroesophageal junction cancer: multi-institution experience. J Clin Oncol. 2023;41(suppl 4):307.","journal-title":"J Clin Oncol"},{"key":"1602_CR43","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1200\/JCO.20.00892","volume":"39","author":"MH Moehler","year":"2021","unstructured":"Moehler MH, Dvorkin M, Boku N, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: JAVELIN Gastric 100. J Clin Oncol. 2021;39:966\u201377.","journal-title":"J Clin Oncol"},{"key":"1602_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1602_CR45","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for first-line advanced gastric cancer: KEYNOTE-062. JAMA Oncol. 2020;6:1571\u201380.","journal-title":"JAMA Oncol"},{"key":"1602_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00230","volume":"8","author":"SJ Klempner","year":"2024","unstructured":"Klempner SJ, Cowden ES, Cytryn SL, et al. PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28\u2009\u2212\u20098, 22C3, and SP263 assays. JCO Precis Oncol. 2024;8. https:\/\/doi.org\/10.1200\/PO.24.00230.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"1602_CR47","doi-asserted-by":"publisher","first-page":"CD004064","DOI":"10.1002\/14651858.CD004064.pub4","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.","journal-title":"Cochrane Database Syst Rev"},{"key":"1602_CR48","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797\u2013805.","journal-title":"Histopathology"},{"key":"1602_CR49","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356.","journal-title":"Nat Med"},{"key":"1602_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"1602_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71347-6","volume":"17","author":"P Ding","year":"2026","unstructured":"Ding P, Chen S, Guo H, et al. A deep learning-based digital biopsy for predicting early recurrence in gastric cancer. Nat Commun. 2026;17. https:\/\/doi.org\/10.1038\/s41467-026-71347-6.","journal-title":"Nat Commun"},{"key":"1602_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41392-025-02374-w","volume":"10","author":"W Yuan","year":"2025","unstructured":"Yuan W, Chen Y, Zhu B, et al. Pancancer outcome prediction via a unified weakly supervised deep learning model. Signal Transduct Target Ther. 2025;10:285. https:\/\/doi.org\/10.1038\/s41392-025-02374-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1602_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10147-024-02683-0","volume":"30","author":"S Kobayashi","year":"2025","unstructured":"Kobayashi S, Nakamura Y, Hashimoto T, et al. Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. Int J Clin Oncol. 2025;30:605\u201354. https:\/\/doi.org\/10.1007\/s10147-024-02683-0.","journal-title":"Int J Clin Oncol"},{"key":"1602_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10120-024-01556-9","volume":"28","author":"CR Iden","year":"2025","unstructured":"Iden CR, Mustafa SM, Ogaard N, et al. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer. 2025;28:83\u201395. https:\/\/doi.org\/10.1007\/s10120-024-01556-9.","journal-title":"Gastric Cancer"},{"key":"1602_CR55","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","volume":"16","author":"A Zaanan","year":"2025","unstructured":"Zaanan A, Didelot A, Broudin C, et al. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study. Nat Commun. 2025;16:6815. https:\/\/doi.org\/10.1038\/s41467-025-62056-7.","journal-title":"Nat Commun"},{"key":"1602_CR56","unstructured":"ClinicalTrials.gov. NCT06157216. Circulating Tumor DNA Minimal Residual Disease-guided Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer (MRD-GATE). Accessed August 30, 2026."},{"key":"1602_CR57","unstructured":"ClinicalTrials.gov. NCT07565857. Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric\/Gastric-Esophageal Cancer (SIGNAL GEC-101). Accessed August 30, 2026."},{"key":"1602_CR58","unstructured":"ClinicalTrials.gov. NCT06939439. Circulating Tumor DNA Monitoring for Postoperative Adjuvant Therapy Decision-Making in Stage III Gastric Cancer (CLAYMORE). Accessed August 30, 2026."}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01602-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01602-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:52:31Z","timestamp":1790700751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01602-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01602-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"21 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"230"}}